Source comparison
Epithalon Sermorelin Protocol Longevity + GH: Peptide Kinetics Comparison
Mechanism Telomerase gene activation (TERT) GHRH receptor agonism (pituitary GH release) Non-overlapping targets. No competitive inhibition Half-Life 2–4 hours (tissue retention ~72h) 8–12 minutes (cleared rapidly) Epithalon can be dosed once daily; sermorelin
This comparison does not assign a generated winner or score.
- Mechanism
- Telomerase gene activation (TERT)
- GHRH receptor agonism (pituitary GH release)
- Non-overlapping targets. No competitive inhibition
- Half-Life
- 2–4 hours (tissue retention ~72h)
- 8–12 minutes (cleared rapidly)
- Epithalon can be dosed once daily; sermorelin requires precise timing
- Peak Effect Window
- 72–96 hours post-dose
- 30–60 minutes post-injection
- Epithalon effects are delayed and cumulative; sermorelin is immediate
- Receptor Downregulation
- None documented (genomic mechanism)
- GHRH receptors desensitize after 4–6 weeks continuous use
- Epithalon can run longer cycles; sermorelin requires cycling or dose breaks
- Measurable Outcome Timeline
- 90–120 days (telomere length via qPCR)
- 14–21 days (IGF-1 elevation, body composition)
- Combined protocols require 3+ month commitment to see epithalon effects
- Bottom Line
- Epithalon is a long-game intervention requiring cyclic dosing and patience. Sermorelin delivers faster metabolic changes but loses efficacy without cycling. Neither works optimally when both are run at maximum dose from day one.